Paper41584508
Recent FDA-approved kinase inhibitors for cancer therapy in 2025: A comprehensive review and perspectives.
Abbas M and 3 others. EXCLI J, 2025. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Recent FDA-approved kinase inhibitors for cancer therapy in 2025: A comprehensive review and perspectives. Papers, record 41584508. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41584508
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Recent FDA-approved kinase inhibitors for cancer therapy in 2025: A comprehensive review and perspectives.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References113
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27226731 | Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma. | Onco Targets Ther | 2016 | https://conductscience.org/library/papers/27226731 | PubMed |
| 2 | 28860885 | Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. | Lung Cancer (Auckl) | 2017 | https://conductscience.org/library/papers/28860885 | PubMed |
| 3 | 39497711 | A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy in IB-IIIB NSCLC patients harboring ALK rearrangement. | Front Oncol | 2024 | https://conductscience.org/library/papers/39497711 | PubMed |
| 4 | 39083791 | Examining the Effectiveness of Electronic Patient-Reported Outcomes in People With Cancer: Systematic Review and Meta-Analysis. | J Med Internet Res | 2024 | https://conductscience.org/library/papers/39083791 | PubMed |
| 5 | 36924668 | Optically activated MEK1/2 inhibitors (Opti-MEKi) as potential antimelanoma agents. | Eur J Med Chem | 2023 | https://conductscience.org/library/papers/36924668 | PubMed |
| 6 | 36795308 | Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors. | Curr Cardiol Rep | 2023 | https://conductscience.org/library/papers/36795308 | PubMed |
| 7 | 38493021 | Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. | Gynecol Oncol | 2024 | https://conductscience.org/library/papers/38493021 | PubMed |
| 8 | 40030100 | HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study. | J Clin Oncol | 2025 | https://conductscience.org/library/papers/40030100 | PubMed |
| 9 | 35390258 | Unraveling the Roles of Protein Kinases in Autophagy: An Update on Small-Molecule Compounds for Targeted Therapy. | J Med Chem | 2022 | https://conductscience.org/library/papers/35390258 | PubMed |
| 10 | 12006504 | Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. | Clin Cancer Res | 2002 | https://conductscience.org/library/papers/12006504 | PubMed |
| 11 | 39840079 | Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39840079 | PubMed |
| 12 | 35900722 | Analysis of FDA's Accelerated Approval Program Performance December 1992-December 2021. | Ther Innov Regul Sci | 2022 | https://conductscience.org/library/papers/35900722 | PubMed |
| 13 | 38101437 | Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial. | Lancet Respir Med | 2024 | https://conductscience.org/library/papers/38101437 | PubMed |
| 14 | 38788184 | Integrating Patient-Reported Outcomes Into the Care of People With Advanced Cancer-A Practical Guide. | Am Soc Clin Oncol Educ Book | 2024 | https://conductscience.org/library/papers/38788184 | PubMed |
| 15 | 23730014 | Imatinib mesylate therapy in patients of chronic myeloid leukemia with Philadelphia chromosome positive: an experience from eastern India. | Indian J Hematol Blood Transfus | 2012 | https://conductscience.org/library/papers/23730014 | PubMed |
| 16 | 38870746 | The development of an archive of patient-reported outcome measures (PROMs) in oncology: The Italian PRO4All project. | Eur J Cancer | 2024 | https://conductscience.org/library/papers/38870746 | PubMed |
| 17 | 39417568 | Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming. | Cancer Control | 2024 | https://conductscience.org/library/papers/39417568 | PubMed |
| 18 | 39248702 | Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers. | Cancer Discov | 2025 | https://conductscience.org/library/papers/39248702 | PubMed |
| 19 | 39281823 | Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy. | Med Drug Discov | 2024 | https://conductscience.org/library/papers/39281823 | PubMed |
| 20 | 38347575 | Unveiling the mechanisms and challenges of cancer drug resistance. | Cell Commun Signal | 2024 | https://conductscience.org/library/papers/38347575 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42749439 | Molecular study of KIT gene that is related to drug resistance in chronic myeloid leukemia patients. | J Genet Eng Biotechnol | 2026 | https://conductscience.org/library/papers/42749439 | PubMed |
| 42496289 | FDA-Approved Drugs Containing Amide Functionality in the Last Five Years (2021-2025): Pharmaceutical Use, Trends and Synthetic Approaches. | Medicines (Basel) | 2026 | https://conductscience.org/library/papers/42496289 | PubMed |
| 42371091 | From data mining to mechanistic prediction: a study on drug-induced lung injury integrating FAERS, machine learning, and network toxicology. | Arch Toxicol | 2026 | https://conductscience.org/library/papers/42371091 | PubMed |
| 42224282 | Multi-omics and pan-cancer analysis revealed common molecular signatures to disclose multitargeted anticancer agents through network pharmacology approach. | PLoS One | 2026 | https://conductscience.org/library/papers/42224282 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41584508
GET https://conductscience.org/api/papers/v1/41584508/references?page=2